Information from drug companies and opinion leaders

British Medical Journal

Volumn 326, Issue 7400, 2003, Pages 1156-1157

  Liberad, Alessandro ^a   Magrini, Nicola ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Ctr Eval Effectiveness Hlth Care   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INDUSTRY; DRUG MARKETING; EDITORIAL; EVIDENCE BASED MEDICINE; HEALTH CARE SYSTEM; MEDICAL INFORMATION; PRIORITY JOURNAL; QUALITY OF LIFE;

BIOMEDICAL AND BEHAVIORAL RESEARCH; EUROPEAN FEDERATION OF PHARMACEUTICAL INDUSTRIES AND ASSOCIATIONS;

DRUG INDUSTRY; DRUG INFORMATION SERVICES; EUROPE; HEALTH SERVICES ACCESSIBILITY; PERIODICALS;

EID: 0038777091     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (14)

1. Figueras A, Laporte JR. Failures of the therapeutic chain as a cause of drug ineffectiveness: promotion, misinformation, and economics work better than needs. BMJ 2003;326:895-6.
2. Collier J. Iheanacho I. The pharmaceutical industry as an informant. Lancet 2002;360:1405-9.
3. Schöffski O, on behalf of the European Federation of Pharmaceutical Industries and Associations. Diffusion of medicines in Europe. EFPIA, September 2002. www.gm.wiso.uni-erlangen.de/ (accessed 27 May 2003).
4. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, Major outcomes in high risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288:2981-97.
5. Zanchetti A, Mancia G. The ALLHAT trial: a verdict or a challenge? J Hypertens 2003;21:223.
6. Wright JT, Davis BR, Cutler JA for the ALLHAT Collaborative Research Group. JAMA 2003;289:2069. (Reply to correspondence on page 2066-8.)
7. Agabiti Rosei P. Quali nuovi insegmamenti dallo studio ALLHAT per il trattamento dell'ipertensione arteriosa. Ipertensione & Prevenzione Cardiovascolare 2002; Dicembre:133-5.
8. Ambrosioni E. Valutarre l'effectiveness pesando tutti gli effetti. Sole 24 Ore Sanità 2003 March 4-10:21.
9. Clinical Evidence. London: BMJ Publishing, 2002. (Issue 8.)
10. Cochrane Library. Issue 4. Oxford: Update software. 2002.
11. Lenzer J. Spin doctors soft pedal data on and hypertensives. BMJ 2003;326:170.
12. Chalmers J. All hats off to ALLHAT: a massive study with clear message. J Hypertens 2003;21:225-8.
13. Fagard RH. The ALLHAT trial: strengths and limitations. J Hypertens 2003;21:229-32.
14. Kaplan NM. The meaning of ALLHAT. J Hypertens 2003;21:233-4.